Related Experiment Video
Updated: May 26, 2026
09:25
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
Mesenchymal chondrosarcoma: clinicopathologic study of 20 cases
Rachel J Shakked1, David S Geller, Richard Gorlick
1Department of Orthopaedic Surgery, Montefiore Medical Center, Bronx, New York 10467, USA.
Archives of Pathology & Laboratory Medicine
|January 3, 2012
Summary
Mesenchymal chondrosarcoma is a rare bone cancer with challenging diagnosis and variable outcomes. Early surgery and chemotherapy may improve patient prognosis, but further research is needed.
Area of Science:
- Orthopedic Oncology
- Skeletal Pathology
- Cancer Biology
Background:
- Mesenchymal chondrosarcoma is a rare, high-grade malignancy.
- It has a unique biphasic histology and a poor prognosis.
- Its rarity and variable survival hinder understanding of its natural history.
Observation:
- This study reviewed 20 cases of mesenchymal chondrosarcoma over 45 years.
- Eighteen tumors originated in bone, primarily craniofacial bones, ribs, and spine.
- Radiographs showed calcified, osteolytic lesions with extraosseous extension.
Findings:
- Histology revealed small round/spindled cells with hyaline cartilage islands.
- Surgery was performed in 85% of patients, with 40% receiving adjuvant treatment.
- Survival rates varied, with 35% living and 40% deceased at follow-up.
Implications:
- Diagnostic challenges include inadequate biopsy samples.
- Sox9 is a potential marker to improve diagnostic specificity.
- Multicenter studies are needed to better understand this rare malignancy and optimize treatment strategies.
